Global Liquid Biopsy Market Size study & Forecast, by Product and Services (Kits & Reagents, Platforms & Instruments, Services) by Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], Other Biomarkers), by

Global Liquid Biopsy Market Size study & Forecast, by Product and Services (Kits & Reagents, Platforms & Instruments, Services) by Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], Other Biomarkers), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Other Cancers), by End-user (Hospitals & Laboratories and Government & Academic Research Centers) and Regional Analysis, 2023-2030

Global Liquid Biopsy Market is valued at approximately USD 4.30 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.50% over the forecast period 2023-2030. The global liquid biopsy market refers to the market for diagnostic tests that detect cancer and other diseases by analyzing genetic material or biomarkers in bodily fluids such as blood, urine, and cerebrospinal fluid. Liquid biopsy tests are non-invasive and provide a less expensive and less risky alternative to traditional tissue biopsies, which involve the removal of tissue samples from the body. The major driving factors for the Global Liquid Biopsy Market are the increasing prevalence of cancer and the growing demand for non-invasive diagnostic tests. Moreover, rising technological advancements and increasing investment in research and development are creating lucrative growth opportunities for the market over the forecast period 2023-2030.

Companies and research institutions are investing heavily in research and development to improve the sensitivity, specificity, and accuracy of liquid biopsy tests, which is driving innovation in the field. For instance, in 2020, Guardant Health invested USD 100 million in a new research and development facility focused on liquid biopsy technology. The company has also announced plans to develop new liquid biopsy tests for use in cancer diagnosis and treatment. Similarly, Grail, a leading liquid biopsy company, has raised over USD 6 billion in funding since 2020, with a significant portion of this investment dedicated to research and development. The company has developed a multi-cancer early-detection test and is currently conducting clinical trials to validate its efficacy. However, the high cost of Liquid Biopsy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Liquid Biopsy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the largest market for liquid biopsy, driven by the presence of several key players in the region, as well as a favorable regulatory environment for the development and commercialization of new technologies. The United States is the biggest contributor to the growth of the North American liquid biopsy market. Asia Pacific is a rapidly growing market for liquid biopsy, driven by the increasing prevalence of cancer in the region and a growing focus on personalized medicine. Countries such as China, Japan, and India are expected to be major contributors to the growth of the Asia Pacific liquid biopsy market.

Major market player included in this report are:
Guardant Health
Grail
Illumina, Inc
Freenome
Biocept, Inc
Natera, Inc.
Cardiff OncologyRainDance Technologies
Adaptive Biotechnologies
Exosome Diagnostics, Inc.

Recent Developments in the Market:
 In November 2021, Grail announced the launch of its large-scale clinical trial, the Circulating Cell-Free Genome Atlas (CCGA) study, which aims to validate the effectiveness of its liquid biopsy technology for the early detection of cancer.
 In August 2020, Guardant Health announced the launch of its liquid biopsy test, Guardant360 CDx, which can detect multiple cancer biomarkers in a single blood sample.

Global Liquid Biopsy Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product and Services, Circulating Biomarker, Cancer Type, End-user, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Product and Services offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product and Services:
Kits & Reagents
Platforms & Instruments
Services
By Circulating Biomarker:
Circulating Tumor Cells
Extracellular Vesicles
Circulating Tumor DNA [ctDNA]
Other Biomarkers
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Other Cancers  
By End-user:
Hospitals & Laboratories
Government & Academic Research Centers

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Guardant Health
Grail
Illumina, Inc
Freenome
Biocept, Inc
Natera, Inc.
Cardiff OncologyRainDance Technologies
Adaptive Biotechnologies
Exosome Diagnostics, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.